Sino Biological Expands Nipah Virus Research Reagents Amid Global Health Concerns

Recent reports of Nipah virus infections in West Bengal, India, have reignited global concern, prompting public health authorities to prioritize research into this high-mortality pathogen. In response, Sino Biological, Inc. has announced the accelerated availability and development of critical research tools to support the global scientific community in combating NiV.

Nipah virus, a member of the Paramyxoviridae family, is classified by the World Health Organization as a priority pathogen due to its epidemic potential and high fatality rate, estimated between 40% to 75%. With no approved vaccines or specific antiviral treatments currently available, the demand for high-quality, biologically active reagents is critical for developing effective countermeasures.

To meet the urgent needs of researchers, Sino Biological has launched a series of high-purity NiV G and F proteins. These proteins are essential for understanding viral entry mechanisms and screening therapeutic antibodies. Additionally, the company is fast-tracking the development of NiV N proteins and pre-fusion and post-fusion F trimer proteins. The N proteins are based on the most recently reported strains, offering improved sequence relevance compared with existing products that contain multiple mutations.

In addition to standard proteins, Sino Biological offers ProPure endotoxin-free versions of NiV G and F proteins, designed for vaccine research applications where immunogen purity and endotoxin control are critical. The company’s expanded portfolio includes specialized reagents available through their Nipah virus research page and detailed protein information at their NiV proteins reagent section.

‘Our mission is to provide the scientific community with the highest quality tools as rapidly as possible when emerging infectious diseases threaten global health,’ said Dr. Rob Burgess, Chief Business Officer at Sino Biological US. ‘By expanding our NiV portfolio, we aim to empower researchers to streamline vaccine discovery and diagnostic breakthroughs.’

The company’s comprehensive approach to supporting Nipah virus research represents a significant development in global preparedness against this deadly pathogen. As researchers worldwide work to develop vaccines and treatments, access to reliable, high-quality research tools becomes increasingly vital for accelerating scientific progress and potentially saving lives during future outbreaks.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Sino Biological Expands Nipah Virus Research Reagents Amid Global Health Concerns.

The post Sino Biological Expands Nipah Virus Research Reagents Amid Global Health Concerns appeared first on citybuzz.